Compass Pathways PLC ADR CMPS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMPS is a good fit for your portfolio.
News
-
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
-
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
-
Why one backer of MDMA therapy sees 'exponential' growth following FDA approval this year
-
FDA issues guidance on psychedelic drug clinical trials
-
Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients
Trading Information
- Previous Close Price
- $7.86
- Day Range
- $7.78–8.07
- 52-Week Range
- $5.01–12.75
- Bid/Ask
- $7.90 / $8.15
- Market Cap
- $542.64 Mil
- Volume/Avg
- 258,441 / 679,296
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Stock Style Box
- —
- Total Number of Employees
- 186
- Website
- https://www.compasspathways.com
Valuation
|
Metric
|
CMPS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.16 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CMPS
|
|---|---|
Quick Ratio | 12.71 |
Current Ratio | 13.33 |
Interest Coverage | −52.40 |
Quick Ratio
CMPS
Profitability
|
Metric
|
CMPS
|
|---|---|
Return on Assets (Normalized) | −46.11% |
Return on Equity (Normalized) | −53.91% |
Return on Invested Capital (Normalized) | −48.05% |
Return on Assets
CMPS
Medical Care Facilities Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
HCA
| HCA Healthcare Inc | Ksbpwhz | Pbgqdv | $83.1 Bil | |
FSNUY
| Fresenius SE & Co KGaA ADR | — | Ntggn | $16.4 Bil | |
FSNUF
| Fresenius SE & Co KGaA | — | Jpljph | $16.4 Bil | |
BDUUY
| Bangkok Dusit Medical Services PCL ADR | — | Lnf | $12.3 Bil | |
FMCQF
| Fresenius Medical Care AG | — | Cwsjpx | $11.9 Bil | |
FMS
| Fresenius Medical Care AG ADR | Lsfw | Lzdcdwk | $11.9 Bil | |
DVA
| DaVita Inc | Dfqvlgqz | Xfjkmml | $11.7 Bil | |
UHS
| Universal Health Services Inc Class B | — | Mdjlr | $11.2 Bil | |
THC
| Tenet Healthcare Corp | Svgjfzxr | Fjdb | $9.5 Bil | |
AMN
| AMN Healthcare Services Inc | Bvyjrgsff | Mbgzpz | $2.2 Bil |